Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
Matthew J. Koster, Cynthia S. Crowson, Rachel Giblon, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 861-867
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
Alain Saraux, Guillermo Carvajal Alegria, Emmanuelle Dernis, et al.
The Lancet Rheumatology (2025)
Closed Access | Times Cited: 3
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
Nils Venhoff, Wolfgang Schmidt, Raoul Bergner, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 6, pp. e341-e350
Closed Access | Times Cited: 39
Immunology of Giant Cell Arteritis
Cornelia M. Weyand, Jörg J. Goronzy
Circulation Research (2023) Vol. 132, Iss. 2, pp. 238-250
Open Access | Times Cited: 34
Novel and potential future therapeutic options in systemic autoimmune diseases
Lili Balogh, Katalin Oláh, Soma Sánta, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation
Hélène Greigert, Coraline Genet, André Ramon, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2905-2905
Open Access | Times Cited: 36
Perspectives of JAK Inhibitors for Large Vessel Vasculitis
Ryu Watanabe, Motomu Hashimoto
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
The Th17 Pathway in Vascular Inflammation: Culprit or Consort?
Marie Robert, Pierre Miossec, A. Hot
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 24
Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice
Marino Paroli, Rosalba Caccavale, Daniele Accapezzato
Cells (2024) Vol. 13, Iss. 3, pp. 267-267
Open Access | Times Cited: 6
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies
Ilaria Ferrigno, Martina Bonacini, Alessandro Rossi, et al.
RMD Open (2024) Vol. 10, Iss. 3, pp. e004600-e004600
Open Access | Times Cited: 5
Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
Guillermo Carvajal Alegria, Mathilde Nicolas, Yannick van Sleen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
JAK inhibitors in rheumatology
Kunihiro Yamaoka, Kenji Oku
Immunological Medicine (2023) Vol. 46, Iss. 3, pp. 143-152
Open Access | Times Cited: 12
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden
Per Eriksson, Oliver Skoglund, Cecilia Hemgren, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Giant Cell Arteritis and Polymyalgia Rheumatica
Desh Nepal, Michael Putman, Sebastian Unizony
Rheumatic Disease Clinics of North America (2023) Vol. 49, Iss. 3, pp. 505-521
Closed Access | Times Cited: 11
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre
Ziyue Zhou, Chenglong Fang, Li Wang, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003985-e003985
Open Access | Times Cited: 4
Vascular disease persistence in giant cell arteritis: are stromal cells neglected?
Maira Karabayas, H. Ibrahim, Anke J. Roelofs, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225270
Open Access | Times Cited: 4
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management
Nicola Farina, Alessandro Tomelleri, Corrado Campochiaro, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 17-26
Open Access | Times Cited: 19
Baricitinib for the treatment of refractory vascular Behçet's disease
Zhimian Wang, Xiaoou Wang, Weiwei Liu, et al.
Clinical Immunology (2023) Vol. 250, pp. 109298-109298
Closed Access | Times Cited: 10
Identification of clonally expanded T-cell receptor sequences in giant cell arteritis
Anna Weber, Michal Zulcinski, Lubna Haroon‐Rashid, et al.
Journal of Autoimmunity (2025) Vol. 151, pp. 103372-103372
Open Access
GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica
William F. Jiemy, Anqi Zhang, Wayel H. Abdulahad, et al.
Annals of the Rheumatic Diseases (2025)
Closed Access
Aortic Disease in Giant Cell Arteritis
Kenneth J. Warrington
Seminars in Arthritis and Rheumatism (2025), pp. 152677-152677
Closed Access
A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis
Robert Zorc, Christopher Redmond, McKella Sylvester, et al.
Annals of the Rheumatic Diseases (2025)
Closed Access
Treatment of Giant Cell Arteritis (GCA)
Alexis Régent, Luc Mouthon
Journal of Clinical Medicine (2022) Vol. 11, Iss. 7, pp. 1799-1799
Open Access | Times Cited: 15
Cranial involvement in giant cell arteritis
Philipp Bösch, Georgina Espígol‐Frigolé, María C. Cid, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 6, pp. e384-e396
Closed Access | Times Cited: 3
Impaired IL-6-induced JAK-STAT signaling in CD4+ T cells associates with longer treatment duration in giant cell arteritis
İdil Esen, Maria Sandovici, Peter Heeringa, et al.
Journal of Autoimmunity (2024) Vol. 146, pp. 103215-103215
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top